The company has reported total income of Rs.129.14 crores during the period ended December 31, 2022 as compared to Rs.157.54 crores during the period ended December 31, 2021.
The OAI classification implies that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Subscribe To Our Newsletter & Stay Updated
